|
Teva Launches First Generic GLP-1 for Obesity
|
Written by: J. Smith |
Hits: 112
|
|
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
|
Written by: J. Smith |
Hits: 137
|
|
FDA Expands Repatha Access to More High-Risk Adults
|
Written by: J. Smith |
Hits: 273
|
|
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
|
Written by: J. Smith |
Hits: 283
|
|
Signos Press Release Raises Questions About FDA Clearance Claims
|
Written by: J. Smith |
Hits: 312
|
|
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
|
Written by: J. Smith |
Hits: 239
|
|
FDA Approves Wegovy for MASH Treatment
|
Written by: J. Smith |
Hits: 255
|
|
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
|
Written by: J. Smith |
Hits: 327
|
|
Mounjaro Shows Heart Health Potential in Landmark Diabetes Trial
|
Written by: J. Smith |
Hits: 203
|
|
Novo Nordisk Lowers Outlook, Names New CEO, and Restructures R&D
|
Written by: J. Smith |
Hits: 387
|
